High-Sensitivity Micro LC-MS/MS Assay Developed for Serum Estradiol
By LabMedica International staff writers Posted on 10 Aug 2016 |

Image: The Eksigent Ekspert micro liquid chromatography (LC) 200 system (Photo courtesy of Sciex).
There are considerable demands to accurately measure estradiol (E2) at low concentrations of less than 20 pg/mL in postmenopausal women, men, pediatric patients, and patients receiving breast cancer treatment.
Automated immunoassays are the most widely used techniques for E2 measurements in clinical laboratories; however, they suffer from poor accuracy and precision at low physiological E2 concentrations. A high-sensitivity, underivatized method has been developed using micro liquid chromatography–mass spectrometry (LC-MS/MS) to reliably measure E2 concentrations below 5 pg/mL by the use of low sample volume.
Scientists at the University of Chicago (IL, USA) used samples for method comparison from leftover samples retrieved from the clinical chemistry laboratory. A total of 290 μL of sample was mixed with internal standard (IS), E2-d4, and extracted with a mixture of hexane/ethyl acetate (90/10) (v/v). After extraction, sample was separated by an Eksigent Ekspert micro LC 200 system with a flow rate of 35 μL/min in a total run time of 3.5 minutes and detected by a QTRAP 6500 mass spectrometer (Sciex, Framingham, MA, USA) in a negative mode using transitions: 271/145 (quantifier) and 271/143 (qualifier). In this method, it was crucial to use HPLC columns with stability at a pH >10.
E2 measurements by LC-MS/MS were compared with the Cobas 8000 E2 II automated immunoassay (Roche Diagnostics, Basel, Switzerland) using 42 plasma samples collected in lithium heparin tubes and with a laboratory-developed indirect radioimmunoassay using 38 serum samples collected in plain serum tubes. The LC-MS/MS method showed good correlation with E2 RIA and modest correlation with E2 Roche Cobas automated immunoassay. The validation study demonstrated broad linear ranges 3.0 to 820 pg/mL. Total precision was below 15% at all quality control (QC) levels, and limit of quantification (LOQ) was 3.0 pg/mL. The study was published in the July 2016 issue of the Journal of Applied Laboratory Medicine.
Related Links:
University of Chicago
Sciex
Roche Diagnostics
Automated immunoassays are the most widely used techniques for E2 measurements in clinical laboratories; however, they suffer from poor accuracy and precision at low physiological E2 concentrations. A high-sensitivity, underivatized method has been developed using micro liquid chromatography–mass spectrometry (LC-MS/MS) to reliably measure E2 concentrations below 5 pg/mL by the use of low sample volume.
Scientists at the University of Chicago (IL, USA) used samples for method comparison from leftover samples retrieved from the clinical chemistry laboratory. A total of 290 μL of sample was mixed with internal standard (IS), E2-d4, and extracted with a mixture of hexane/ethyl acetate (90/10) (v/v). After extraction, sample was separated by an Eksigent Ekspert micro LC 200 system with a flow rate of 35 μL/min in a total run time of 3.5 minutes and detected by a QTRAP 6500 mass spectrometer (Sciex, Framingham, MA, USA) in a negative mode using transitions: 271/145 (quantifier) and 271/143 (qualifier). In this method, it was crucial to use HPLC columns with stability at a pH >10.
E2 measurements by LC-MS/MS were compared with the Cobas 8000 E2 II automated immunoassay (Roche Diagnostics, Basel, Switzerland) using 42 plasma samples collected in lithium heparin tubes and with a laboratory-developed indirect radioimmunoassay using 38 serum samples collected in plain serum tubes. The LC-MS/MS method showed good correlation with E2 RIA and modest correlation with E2 Roche Cobas automated immunoassay. The validation study demonstrated broad linear ranges 3.0 to 820 pg/mL. Total precision was below 15% at all quality control (QC) levels, and limit of quantification (LOQ) was 3.0 pg/mL. The study was published in the July 2016 issue of the Journal of Applied Laboratory Medicine.
Related Links:
University of Chicago
Sciex
Roche Diagnostics
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
- Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more